Dosage and administration
Apply to underarms only.
Apply to underarms only.
Aluminum zirconium tetrachlorohydrex gly 20%
Antiperspirant
For external use only.
Do not use on broken skin
Ask a doctor before use if you have kidney disease
Stop use if rash or irriation occurs
If swallowed, get medical help or contact a Poison Control Center right away.
Apply to underarms only.
cyclopentasiloxane, stearyl alcohol, PPG-14 butyl ether, Talc, parfum (fragrance), PEG-8 distearate, hydrogenated castor oil, tocopheryl acetate, aloe barbadensis leaf extract, hydrogen peroxide, silica dimethicone silylate, sodium ascorbate, calcium disodium edta, aqua ((water) eau), citric acid, bht, mannitol, silica, sodium starch octenylsuccinate, citronellol, geraniol, coumarin, limonene, linalool, isoeugenol, citral
1-888-8-MITCHUM
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 5eb9f24b-9328-475e-af0a-18021935eb6a | Product name | 1 | 20180220 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 10967-589-41 | 2019-11-27 | C162847 | 48780-1 | 9855e2a2-3c81-60a7-e053-dbdaa90a05bd | Mens Mitchum Advanced Invisible Solid Antiperspirant Deodorant (Clean Control)- 2.7 oz. |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 10967-589-41 | Womens Mitchum Advanced Invisible Antiperspirant DeodorantSolid Clean Control | 76 g in 1 CANISTER | STICK | 76 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 10967-589 | WOMENS MITCHUM ADVANCED INVISIBLE ANTIPERSPIRANT DEODORANT SOLID CLEAN CONTROL (ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY) STICK [REVLON CONSUMER PRODUCTS CORP] | 1 | Legacy NDC, 1 package rows | 20140131_9af704f6-816f-4042-96d9-5519a555d878.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY | ACTIVE INGREDIENT | 8O386558JE | 1 | |
| ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY | ACTIVE MOIETY | 8O386558JE | 1 | |
| .ALPHA.-TOCOPHEROL ACETATE | INACTIVE INGREDIENT | 9E8X80D2L0 | 1 | |
| ALOE VERA LEAF | INACTIVE INGREDIENT | ZY81Z83H0X | 1 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 1 | |
| CITRAL | INACTIVE INGREDIENT | T7EU0O9VPP | 1 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| CITRONELLAL | INACTIVE INGREDIENT | QB99VZZ7GZ | 1 | |
| COUMARIN | INACTIVE INGREDIENT | A4VZ22K1WT | 1 | |
| CYCLOMETHICONE 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 1 | |
| EDETATE CALCIUM DISODIUM ANHYDROUS | INACTIVE INGREDIENT | 8U5D034955 | 1 | |
| GERANIOL | INACTIVE INGREDIENT | L837108USY | 1 | |
| HYDROGEN PEROXIDE | INACTIVE INGREDIENT | BBX060AN9V | 1 | |
| HYDROGENATED CASTOR OIL | INACTIVE INGREDIENT | ZF94AP8MEY | 1 | |
| ISOEUGENOL | INACTIVE INGREDIENT | 5M0MWY797U | 1 | |
| LIMONENE, (+)- | INACTIVE INGREDIENT | GFD7C86Q1W | 1 | |
| LINALOOL, (+)- | INACTIVE INGREDIENT | F4VNO44C09 | 1 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 1 | |
| PEG-8 DISTEARATE | INACTIVE INGREDIENT | 7JNC8VN07M | 1 | |
| PPG-14 BUTYL ETHER | INACTIVE INGREDIENT | R199TJT95T | 1 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 1 | |
| SODIUM ASCORBATE | INACTIVE INGREDIENT | S033EH8359 | 1 | |
| STEARYL ALCOHOL | INACTIVE INGREDIENT | 2KR89I4H1Y | 1 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 10967-589 | 10967-589-41 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LIMONENE, (+)- | LIMONENE, (+)- | GFD7C86Q1W | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / SUBLINGUAL | 32.4 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CONCENTRATE / INTRAVENOUS | 220 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / INTRAVENOUS | 15400 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SUSPENSION / OPHTHALMIC | ADJ PH | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / BUCCAL | 360 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | LOZENGE / ORAL | 120 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 980.4 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | LOTION / TOPICAL | 0.85 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / INTRA-ARTICULAR | ADJ PH | ||
| TALC | TALC | 7SEV7J4R1U | DROPS / ORAL | NA | ||
| HYDROGENATED CASTOR OIL | HYDROGENATED CASTOR OIL | ZF94AP8MEY | TABLET, FILM COATED / ORAL | 17 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SPRAY / NASAL | 41.5 mg | ||
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | CREAM / VAGINAL | 425 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CREAM / TOPICAL | 6 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, DELAYED RELEASE PARTICLES / ORAL | 170 mg | ||
| TALC | TALC | 7SEV7J4R1U | POWDER / TOPICAL | 9235 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 60 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAOCULAR | 1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED / ORAL | 3 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION / SUBCUTANEOUS | 28 mg | ||
| TALC | TALC | 7SEV7J4R1U | GRANULE, FOR SUSPENSION / ORAL | 296 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | AEROSOL, FOAM / TOPICAL | 1 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | SOLUTION / INTRAMUSCULAR | 0.05 %w/v | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION / SUBCUTANEOUS | 26 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SODIUM ASCORBATE | SODIUM ASCORBATE | S033EH8359 | CAPSULE / ORAL | 6 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / SUBCUTANEOUS | 675 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | INJECTION, SOLUTION, CONCENTRATE / IRRIGATION | 1 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, COATED / ORAL | 176 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | FILM, SOLUBLE / ORAL | 0.06 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / BUCCAL | 15 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | GEL, METERED / TOPICAL | 4 mg | ||
| HYDROGENATED CASTOR OIL | HYDROGENATED CASTOR OIL | ZF94AP8MEY | LIQUID / TOPICAL | 0.24 %w/w | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | OINTMENT / TOPICAL | 1 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL, FOAM / TOPICAL | 144 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | CONCENTRATE / ORAL | 5.3 mg/1ml | ||
| SODIUM ASCORBATE | SODIUM ASCORBATE | S033EH8359 | INJECTION, POWDER, FOR SOLUTION / INTRADERMAL | 0.5 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SYSTEM / TRANSDERMAL | 35 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / SUBLINGUAL | 495 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SWAB / TOPICAL | 0.5 %w/w | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION, EXTENDED RELEASE / ORAL | 2464.6 mg | ||
| TALC | TALC | 7SEV7J4R1U | SUSPENSION / ORAL | 234 mg | ||
| STEARYL ALCOHOL | STEARYL ALCOHOL | 2KR89I4H1Y | AEROSOL, FOAM / TOPICAL | 37 mg | ||
| SODIUM ASCORBATE | SODIUM ASCORBATE | S033EH8359 | SUSPENSION, EXTENDED RELEASE / ORAL | 33 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SOLUTION / ORAL | 336 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 616 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 4.35 %w/w | ||
| TALC | TALC | 7SEV7J4R1U | TABLET, DELAYED RELEASE / ORAL | 349 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOLUTION / ORAL | 14 mg | ||
| SODIUM ASCORBATE | SODIUM ASCORBATE | S033EH8359 | INJECTION / INTRAVENOUS | 625 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SPRAY, METERED / NASAL | 0.1 mg/1ml | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 0.02 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 2652f533-5dc8-4a43-8164-2ef06ccf3892 | 9af704f6-816f-4042-96d9-5519a555d878 | 2014-01-31 | Warnings | 2652f533-5dc8-4a43-8164-2ef06ccf3892 9af704f6-816f-4042-96d9-5519a555d878 |
Adverse event summaries are temporarily unavailable. Other product information remains available.